Organisation paid for research Program year 2025 Source: CMS Open Payments

Core Clinical Research

Neither a doctor nor a teaching hospital

Research payments

$753,766

178 payments

Through program year 2025, Core Clinical Research is reported as receiving $753,766 in research payments, across 178 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$261,126	57
2024	Research	$211,833	22
2023	Research	$203,368	27
2022	Research	$56,908	13
2021	Research	$13,281	25
2020	Research	$3,836	14
2019	Research	$3,414	20

Breakdown

Who paid Research payments · program years 2019–2025

ACADIA Pharmaceuticals Inc $471,548 47 payments
BioXcel Therapeutics, Inc. $179,153 8 payments
E.R. Squibb & Sons, L.L.C. $37,893 2 payments
Boehringer Ingelheim Pharmaceuticals, Inc. $18,647 6 payments
Boehringer Ingelheim RCV GmbH & Co KG $12,956 18 payments
Boehringer Ingelheim Pharma GmbH & Co.KG $10,694 9 payments
Boehringer Ingelheim International GmbH $9,958 46 payments
AbbVie, Inc. $7,429 10 payments
Allergan Inc. $4,528 8 payments
Pfizer Inc. $745 16 payments

Studies the money was for Research payments · program years 2019–2025

Acp-103-069 $328,259 23 payments
Bxcl501401 $179,153 8 payments
Acp-103-070 $130,789 23 payments
An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in De Novo Subjects With DSM-5 Schizophrenia $37,893 2 payments
Proof of concept and DRF in BPD $19,134 11 payments
Acp-103-069 $12,500 1 payment
Proof of concept and DRF in MDD $10,551 8 payments
BI 425809 Pivotal efficacy study 1 $9,239 5 payments
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder $5,492 38 payments
Phase II dose finding trial in monotherapy for MDD $3,836 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.